Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation

Open access

Published version of a preprint

Abstract

Purpose: Liquid biopsy (LBx) for tumor profiling is increasingly used, but concerns remain regarding negative results. A lack of results may truly reflect tumor genomics, or it may be a false negative that would be clarified by tissue testing. A method of distinguishing between these scenarios could help clarify when follow-on tissue testing is valuable. Experimental Design: Here we evaluate circulating tumor DNA (ctDNA) tumor fraction (TF), a quantification of ctDNA in LBx samples, for utility in identifying true negative results. We assessed concordance between LBx and tissue-based results, stratified by ctDNA TF, in a real-world genomic dataset of paired samples across multiple disease types. We also evaluated the frequency of tissue results identifying driver alterations in patients with lung cancer after negative LBx in a real-world clinicogenomic database. Results: The positive percent agreement and negative predictive value between liquid and tissue samples for driver alterations increased from 63% and 66% for all samples to 98% and 97% in samples with ctDNA TF ≥1%. Among 505 patients with lung cancer with no targetable driver alterations found by LBx who had subsequent tissue-based profiling, 37% had a driver, all of which had ctDNA TF <1%. Conclusions: Patients with lung cancer with negative LBx and ctDNA TF ≥1% are unlikely to have a driver detected on confirmatory tissue testing; such informative negative results may benefit instead from prompt treatment initiation. Conversely, negative LBx with ctDNA TF <1% will commonly have a driver identified by follow-up tissue testing and should be prioritized for reflex testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-23-3321

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. ctDNA tumor fraction identifies liquid biopsy samples with high concordance to tissue. PPA and NPV of liquid biopsy with results at any ctDNA TF (A), results with ctDNA TF≥1% (B), and results with ctDNA TF <1% (C).
Figure 1. ctDNA tumor fraction identifies liquid biopsy samples with high concordance to tissue. PPA and NPV of liquid biopsy with results at any ctDNA TF (A), results with ctDNA TF≥1% (B), and results with ctDNA TF <1% (C).CC BY-NC-ND · PubMed Central
Figure 2. Data from a real-world CGDB was analyzed to understand the value of reflex tissue testing. Patients with liquid biopsy prior to 1L therapy were analyzed for rates of driver detection. Patients who were driver negative by liquid biopsy who subsequently received tissue biopsy CGP were further analyzed to understand their treatment patterns and outcomes.
Figure 2. Data from a real-world CGDB was analyzed to understand the value of reflex tissue testing. Patients with liquid biopsy prior to 1L therapy were analyzed for rates of driver detection. Patients who were driver negative by liquid biopsy who subsequently received tissue biopsy CGP were further analyzed to understand their treatment patterns and outcomes.CC BY-NC-ND · PubMed Central
Figure 3. Negative liquid biopsy results are frequently false negatives when confirmed by tissue-based testing. A, Among patients tested prior to initiation of 1L therapy, liquid biopsy–based CGP identifies targetable drivers in approximately 40% of patients with NSCLC. B, Patients with no drivers identified by liquid biopsy had a driver mutation newly identified upon subsequent tissue-based CGP.
Figure 3. Negative liquid biopsy results are frequently false negatives when confirmed by tissue-based testing. A, Among patients tested prior to initiation of 1L therapy, liquid biopsy–based CGP identifies targetable drivers in approximately 40% of patients with NSCLC. B, Patients with no drivers identified by liquid biopsy had a driver mutation newly identified upon subsequent tissue-based CGP.CC BY-NC-ND · PubMed Central
Figure 4. ctDNA tumor fraction informs the relative benefit of confirmatory tissue-based testing. Left: Patients with low ctDNA TF (<1%, n = 56) and no driver alterations detected have underlying driver alterations in 51.8% of cases when assessed by subsequent tissue CGP. Right: Zero patients with high ctDNA TF (≥1%) and subsequent tissue CGP (0/24) had driver alterations identified by confirmatory testing.
Figure 4. ctDNA tumor fraction informs the relative benefit of confirmatory tissue-based testing. Left: Patients with low ctDNA TF (<1%, n = 56) and no driver alterations detected have underlying driver alterations in 51.8% of cases when assessed by subsequent tissue CGP. Right: Zero patients with high ctDNA TF (≥1%) and subsequent tissue CGP (0/24) had driver alterations identified by confirmatory testing.CC BY-NC-ND · PubMed Central
Figure 5. Timely confirmatory testing of TBx following negative LBx results leads to more frequent use of targeted therapies and prolonged clinical benefit. A, Among patients with negative LBx receiving confirmatory TBx CGP before initiation of 1L therapy, 41 (17%) received a matched targeted therapy, while only 9 (4%) of those with TBx CGP after 1L did so. B, When excluding patients with KRAS driver alterations due to the relatively recent approval of therapies for KRAS alterations, 63% of patients with confirmatory TBx CGP prior to 1L received a matched targeted therapy, compared with 27% of those with TBx CGP after 1L. C, The rwPFS among patients with TBx CGP before 1L is 24.2 months. D, The rwOS among these patients is 45.8 months.
Figure 5. Timely confirmatory testing of TBx following negative LBx results leads to more frequent use of targeted therapies and prolonged clinical benefit. A, Among patients with negative LBx receiving confirmatory TBx CGP before initiation of 1L therapy, 41 (17%) received a matched targeted therapy, while only 9 (4%) of those with TBx CGP after 1L did so. B, When excluding patients with KRAS driver alterations due to the relatively recent approval of therapies for KRAS alterations, 63% of patients with confirmatory TBx CGP prior to 1L received a matched targeted therapy, compared with 27% of those with TBx CGP after 1L. C, The rwPFS among patients with TBx CGP before 1L is 24.2 months. D, The rwOS among these patients is 45.8 months.CC BY-NC-ND · PubMed Central
Figure 6. A clinical paradigm distinguishing actionable liquid biopsy results. For patients with liquid biopsy results, actionable drivers can guide targeted therapy use. Results that are negative for driver alterations can be distinguished by tumor fraction: a result with a low ctDNA TF (<1%) is an indeterminate negative where confirmatory tissue may likely reveal a driver alteration, whereas a result with high ctDNA TF (≥1%) is an informative negative that provides confidence in the true absence of driver alterations in the tumor.
Figure 6. A clinical paradigm distinguishing actionable liquid biopsy results. For patients with liquid biopsy results, actionable drivers can guide targeted therapy use. Results that are negative for driver alterations can be distinguished by tumor fraction: a result with a low ctDNA TF (<1%) is an indeterminate negative where confirmatory tissue may likely reveal a driver alteration, whereas a result with high ctDNA TF (≥1%) is an informative negative that provides confidence in the true absence of driver alterations in the tumor.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 118

Metadata

Authors
Rolfo, C. D., Madison, R. W., Pasquina, L. W., Brown, D. W., Huang, Y., Hughes, J. D., Graf, R. P., Oxnard, G. R., & Husain, H.
Affiliations
  • Tisch Cancer Institute (US)
  • Foundation Medicine (United States) (US)
  • Boston Medical Center (US)
  • Moores Cancer Center (US)
Corresponding author
Rolfo, Christian D.
Venue
Clinical Cancer Research
Published
2024-03-25
Volume
30
Issue
11
Pages
2452-2460
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4393144776
Cited by
104
References
30
Citations by year
2026: 37 · 2025: 55 · 2024: 12
FWCI
20.86
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • International Association for the Study of Lung Cancer
  • Lung Cancer Research Foundation
  • Regeneron Pharmaceuticals
  • Boston Pharmaceuticals
  • Invitae
  • EMD Serono
  • Foundation Medicine
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
circulating tumor DNA, tumor fraction, liquid biopsy, false-negative results, driver alterations, lung cancer, reflex testing, cancer genomics
MeSH terms
Liquid Biopsy, Circulating Tumor DNA, Female, Humans, Lung Neoplasms, Mutation, Neoplasms, Biomarkers, Tumor, Genomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-23-3321
The paper
Rolfo, C. D., Madison, R. W., Pasquina, L. W., Brown, D. W., Huang, Y., Hughes, J. D., Graf, R. P., Oxnard, G. R., & Husain, H. (2024). Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-23-3321

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.